Skip to main content

Advertisement

Log in

Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

The rat neonatal ventral hippocampal (VH) ibotenic lesion model has been proposed as a developmental model of schizophrenia, based on evidence that it encompasses aspects of the disorder including psychomotor agitation (hyperactivity), deficits in prepulse inhibition (PPI), and deficits in social interaction (SI), measures presumed to reflect positive symptoms, sensory gating deficits and negative symptoms, respectively. However, validation of the model as a predictive pharmacological screening tool has been minimal.

Objective

Determine the effects of a chronic 3-week low dose treatment of clozapine or risperidone on locomotor hyperactivity, PPI and SI in lesioned and control rats.

Results

Both clozapine, 2.5 mg/kg per day IP and risperidone, 0.1 mg/kg per day IP, reversed lesion-induced locomotor hyperactivity; however, the compounds also decreased locomotor activity in the non-lesioned controls. Clozapine 2.5 mg/kg per day and risperidone 0.1 mg/kg per day significantly attenuated lesion-induced PPI deficits. Neither compound induced a significant attenuation of lesion-induced SI deficits. In order to see if SI deficits required a higher dose of an antipsychotic, the dose of clozapine was increased to 4 mg/kg per day; however this dose induced such marked decreases in the activity and startle responses in the control rats, i.e. up to 74% decrease, that the effects on the lesioned rats could not be adequately interpreted.

Conclusions

These data add further support to the neonatal VH lesion model as a predictive pharmacological screening assay for identifying compounds effective in the treatment of positive symptoms of schizophrenia. However, the usefulness of the model in detecting compounds effective in treating negative symptoms of schizophrenia is still in question.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • American Psychiatric Association (2000) Practice guidelines for the treatment of psychiatric disorder: compendium 2000. American Psychiatric Association, Washington D.C.

    Google Scholar 

  • Becker A, Grecksh G, Bernstein H-G, Höllt V, Bogerts B (1999) Social behavior in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology 144:333–338

    Article  CAS  PubMed  Google Scholar 

  • Chambers RA, Moore J, McEvoy JP, Levin ED (1996) Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology 15:587–594

    CAS  PubMed  Google Scholar 

  • Harrison PJ (1999) The neuropathology of schizophrenia a critical review of the data and their interpretation. Brain 122:593–624

    Article  PubMed  Google Scholar 

  • Joffe G, Venalainen E, Tupala J, Hiltunen O, Wahlbeck K, Gadeke R, Rimon R (1996) The effect of clozapine on the course of illness in chronic schizophrenia: focus on treatment outcome in out-patients. Int Clin Psychopharmacol 11:265–272

    CAS  PubMed  Google Scholar 

  • Kapur S, Remington G (2001) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503–517

    Article  CAS  Google Scholar 

  • Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286–293

    Google Scholar 

  • Kapur S, Vanderspek SC, Brownlee BA, Nobriega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625–631

    Article  CAS  PubMed  Google Scholar 

  • Kumari V, Soni W, Sharma T (1999) Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry 156:1046–1051

    CAS  PubMed  Google Scholar 

  • Kumari V, Soni W, Sharma T (2002) Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics. Schizophr Res 55:139–146

    Article  Google Scholar 

  • Le Pen G, Moreau J-L (2002) Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropscyhopharmacology 27:1–11

    Article  Google Scholar 

  • Lipska BK, Weinberger DR (1994) Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology 10:199–205

    CAS  PubMed  Google Scholar 

  • Lipska BK, Weinberger DR (2000) To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23:223–239

    CAS  PubMed  Google Scholar 

  • Lipska BK, Jaskiw GE, Weinberger DR (1993) Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 9:67–75

    CAS  PubMed  Google Scholar 

  • Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR (1995) Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology 122:35–43

    CAS  PubMed  Google Scholar 

  • Pearlson GD (1999) New insights on the neuroanatomy of schizophrenia. Curr Psychiatr Rep 1:41–45

    CAS  PubMed  Google Scholar 

  • Rowe WB, Spreekmeester E, Meaney MK, Quirion R, Rochford J (1998) Reactivity to novelty in cognitively-impaired and cognitively-unimpaired aged rats and young rats. Neuroscience 83:669–680

    Article  CAS  PubMed  Google Scholar 

  • Sams-Dodd F, Lipska BK, Weinberger DR (1997) Neontal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology 132:303–310

    Article  CAS  PubMed  Google Scholar 

  • Volavka J, Czobor P, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA (2002) Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159:255–262

    Article  PubMed  Google Scholar 

  • Wilson WH (1996) Time required for initial improvement during clozapine treatment of refractory schizophrenia. Am J Psychiatry 153:951–952

    CAS  PubMed  Google Scholar 

  • Zhang W, Bymaster FP (1999) The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5-HT2A and muscarinic receptors. Psychopharmacology 141:267–278

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lynne E. Rueter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rueter, L.E., Ballard, M.E., Gallagher, K.B. et al. Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology 176, 312–319 (2004). https://doi.org/10.1007/s00213-004-1897-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-004-1897-4

Keywords

Navigation